NTSAD retweeted
Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency. #canavandisease #ukmedicines #innovation
More information: myrtellegtx.com/myrtelles-ra…
NTSAD retweeted
In the latest #OnRarePodcast, we share a heartwarming, funny and poignant conversation with Cliff and Noreen, the parents of Dylan, their playful 15-year-old son living with #Canavan disease. Listen here: apple.co/3R6uZsp
NTSAD retweeted
The ULF is partnering with other Leukodystrophy advocacy groups worldwide over the course of the month to spread Leukodystrophy Awareness!
#ULF #LeukodystrophyAwarenessMonth #UnitedLeukodystrophyFoundation #notgivingup #ShineALightOnLeukodystrophy
NTSAD retweeted
We're thrilled to share early positive data from our gene therapy clinical trial in Canavan disease. We are encouraged by the data and hopeful we will be able to provide an option for children with this fatal genetic disorder. Read more: https://nitter.cf/t.co/MweGXZFb6m
NTSAD retweeted
Today, we stand with the GM1 community in celebrating the 1st International #GM1 Awareness Day. We share your vision of bringing advocacy, awareness & hope to patients & families. We're inspired by you & are deeply committed to finding a potential treatment. #gm1day #RareDisease
NTSAD retweeted
This morning at #ASGCT22, we presented new interim data from cohort 1 of our #Imagine1 study in patients with GM1 #gangliosidosis.
We continue to be encouraged by the potential promise PBGM01 offers for patients. Read more at passagebio.com/investors-and…
#GM1 #GeneTherapy
Join the #RareDisease community for a tweetchat featuring your favorite physicians talking #RareDiseaseDay, the patient/physician connection & more! Follow NORD’s Twitter or #RDDChat22 between 6:30-7:00pm ET Monday, February 28, 2022.
NTSAD retweeted
Today at #WorldSymposia, we presented new interim clinical data from our #Imagine1 study in patients with #GM1gangliosidosis. Management to host conference call & webcast at 1pm ET on Friday, Feb. 11th.
Read more: https://nitter.cf/t.co/zBd2fS1ar5
#GM1 #RareDiseaseMonth #GeneTherapy
NTSAD retweeted
Today we announced corporate updates and fiscal third quarter 2021 financial results. We look forward to continuing to advocate for and working towards treatments for rare fatal pediatric diseases. Read the full release here: https://nitter.cf/t.co/qGSzJjEDa8 $SIOX
NTSAD retweeted
We have received FDA Fast Track Designation for our #GeneTherapy, AXO-AAV-GM2, for the treatment of #TaySachs and #Sandhoff diseases, joining Fast Track Designation for AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. Read more: https://nitter.cf/t.co/UtlWOo8WdU
.@NTSAD's annual Imagine & Believe reception will be held on October 28 at the Royal Sonesta Boston. There will be a free virtual Imagine & Believe event on November 3 from 7-8pm ET. More information here: https://nitter.cf/t.co/yufYxEVqpr
NTSAD retweeted
It’s #TaySachsAwarenessMonth – a critical time to rally support for families impacted by this disease worldwide. Babies with infantile #TaySachs often appear healthy at birth, and within the first few months of life parents begin to see initial signs of the disease. Learn more:
NTSAD retweeted
September is Newborn Screening Awareness Month! #newbornscreening is a critical public health program that facilitates the screening of babies for serious conditions for which early interventions or treatments are available. Learn more about this #2021NBS:
NTSAD retweeted
Today, we announced the dosing of the first Type I (early infantile) patient, the most severe form of #GM1 gangliosidosis, in our ongoing study of AXO-AAV-GM1 #GeneTherapy. We are continuing to screen and enroll Type I patients. More here: https://nitter.cf/t.co/A1VdgU8ax0 $SIOX
NTSAD retweeted
Today we provided a corporate update and financial results for our fiscal first quarter ending June 30, 2021. Read more about our progress and upcoming milestones in #GM1 gangliosidosis, #TaySachs and #Sandhoff diseases, and #Parkinsons disease here: https://nitter.cf/t.co/ttC4hbqqBO $SIOX
NTSAD retweeted
Types of #TaySachs/#Sandhoff diseases include infantile, juvenile and late-onset. Our #GeneTherapy has the potential to target both infantile and juvenile forms of the disease. Learn more about the different forms from @NTSAD here: https://nitter.cf/t.co/8IRmP3koip
NTSAD retweeted
Dr. Kakkis @EveryLifeOrg makes a convincing argument for using biomarkers and the @US_FDA Accelerated Approval process to speed up innovation in #raredisease therapies. @NTSAD
Opinion: The biomedical research community would not be where it is today without striving for progress over perfection. buff.ly/3yJAa8r
NTSAD retweeted
#GM2 gangliosidosis is a rare and fatal pediatric disorder that progressively destroys nerve cells in the brain and spinal cord. Learn more about our work in collaboration with @UMassMedical to reach the entire CNS with our #GeneTherapy: https://nitter.cf/t.co/zVqFO0oH1y























